Drug Trial Radar · NCT07943377
Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Dec 14, 2026
Primary completion
Aug 6, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Aligos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of \[14C\]ALG-000184 and a Single Intravenous Dose of \[13C7,15N1\]ALG-001075 (Part C)
Conditions
- Healthy Participants
Interventions
ALG-000184Drug
Single or multiple doses of ALG-000184
PlaceboDrug
Single or multiple doses of Placebo
[14C]ALG-000184Radiation
Single oral dose of \[14C\]ALG-000184
[13C7,15N1]ALG-001075Radiation
Single micodose of \[13C7,15N1\]ALG-001075 with combination of \[14C\]ALG-000184
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability (Part A and B)Time frame: From enrollment to end of treatment at 10 days
- PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
- PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
- PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
- PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
- PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
- PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
- Total radioactivity recovery (fet1-t2) in urine and feces (Part C)Time frame: From enrollment to end of treatment at 10 days
- Metabolic profiles of ALG-000184 (Part C)Time frame: From enrollment to end of treatment at 10 days
- Identification of ALG-000184 (Part C)Time frame: From enrollment to end of treatment at 10 days
- Bioavailability of ALG-001075 (Part C)Time frame: From enrollment to end of treatment at 10 days
- PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
- PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
- PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
- PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
- PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aligos Investigational Site
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.